Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing
06/11/20, 2:14 PM
Location
Money raised
$26 million
Round Type
series a
Cullinan Oncology LLC and PDI Therapeutics, a portfolio company of Avalon Ventures, today announced a collaboration to bring CLN-619, a first-in-class monoclonal antibody reinvigorating the MICA/NKG2D axis into human clinical testing. As a result of the transaction, Cullinan MICA, Inc., a Cullinan Oncology portfolio company, will assume operational control of the asset.
Company Info
Company
Cullinan Oncology And Pdi Therapeutics
Location
cambridge, maryland, united states
Additional Info
Cullinan’s business model is predicated on distributing risk while maximizing the optionality inherent in novel science through the construction of a diversified portfolio of internally developed as well as externally sourced oncology assets. Cullinan’s scalable model minimizes the fixed costs and inefficiencies of many traditional development approaches through strategic partnerships and a shared services platform. For more information, visit www.cullinanoncology.com